6640--LAB - CEPHEID MRSA PCR MOLECULAR TESTING

Active

Contract Opportunity

This is a notice of intent to award a sole source contract and is not a request for quotes.
The Department of Veterans Affairs (DVA) Network Contracting Office NCO2, on behalf of VISN2 South Medical Centers, intends to award a Firm Fixed Price (FFP), sole source action to:
Name of Contractor:
Cepheid Inc.
Street Address:
904 East Caribbean Drive
City, State, Zip:
Sunnyvale, CA 94089

The following DVA VISN2 south medical centers have a recurring requirement for Polymerase Chain Reaction (PCR) Molecular Diagnostic testing on a cost per reportable / test basis.

Brooklyn VA Medical Center
800 Poly Place, Brooklyn, NY 11209-7104

Castle Point VA Medical Center
41 Castle Point Rd., Wappingers Falls, NY 12590-7004

East Orange VA Medical Center
385 Tremont Avenue, East Orange, NJ 07018-1023

Franklin Delano Roosevelt Hospital
2094 Albany Post Road, Montrose, NY 10548-1454

James J. Peters VA Medical Center
130 W Kingsbridge Rd, Bronx, NY 10468-3904

Margaret Cochran VA Medical Center
423 East 23rd Street, New York, NY 10010-5011

Northport VA Medical Center
79 Middleville Road, Building 200,Northport, NY 11768-2200

This requirement is for continued use of government-owned and contractor-provided Cepheid GeneXpert and Infinity instruments, maintenance, reagents, controls, consumables/ disposables and supplementary items required for complete PCR molecular testing, on a long-term basis.

Market research was conducted in accordance with Part 10 of the Revolutionary FAR Overhaul (RFO), reviewing the offerings and capabilities available through the current marketplace. In accordance with FAR Part 6.103-1(b), it has been determined that only one source is reasonably capable of fulfilling this action as required; Cepheid is the sole vendor that can provide maintenance and testing supplies for existing DVA owned equipment, as well as provide instruments with comprehensive test menus inclusive of: MRSA, C.difficile (with and without epidemic strain 027), COVID-19, influenza, RSV, Chlamydia trachomatis/Neisseria gonorrhea. MTB and RIF resistance, strep group A, T.vaginalis, Carbapenemase producing organism identification, MRSA/S.aureus blood culture identification, and MVP identification on the primary analyzers, and Clostridium difficile with identification of epidemic strain 027 and COVID-19, Influenza A, B, RSV on the secondary analyzers.

Market research failed to produce additional sources capable of fulfilling this requirement as a whole.
In accordance with the Revolutionary FAR Overhaul (RFO) this notice of intent to sole source with justification to limit competition, satisfies the public posting requirements of 6.301.
Veterans Health Administration prohibits the use of gray market items in their Medical Centers. Gray market items are considered to be items outside of the original equipment manufacturer s intended distribution channels.
This notice is not a request for quotes; however, all responsible sources may submit a capability statement which shall be considered by the Government. All capability statements must be received by no later than 12:00 PM Eastern Standard Time on May 22, 2026. Responses to be submitted to Lindsay Goldsmith, Contracting Officer at lindsay.goldsmith@va.gov. A determination by the Government not to compete this proposed contract based on responses to this notice is solely within the discretion of the Government.

Attachments/Links